{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:43:26Z","timestamp":1787917406934,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000142","name":"Arthritis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006538","name":"Arthritis Society Canada","doi-asserted-by":"publisher","award":["SOG-22-192"],"award-info":[{"award-number":["SOG-22-192"]}],"id":[{"id":"10.13039\/501100006538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaut.2026.103538","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:08:09Z","timestamp":1772579289000},"page":"103538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Perinatal use of targeted synthetic DMARDs and maternal-neonatal outcomes in autoimmune disease: A population-based cohort study"],"prefix":"10.1016","volume":"159","author":[{"given":"Vienna","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Sayre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn J.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2205-2683","authenticated-orcid":false,"given":"Mary A.","family":"De Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2026.103538_bib1","series-title":"Disease-Modifying Antirheumatic Drugs (DMARD). StatPearls","author":"Benjamin","year":"2024"},{"issue":"8","key":"10.1016\/j.jaut.2026.103538_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081876","article-title":"Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: latest updates and potential strategy for fighting COVID-19","volume":"9","author":"Massalska","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2026.103538_bib3","series-title":"PRODUCT MONOGRAPH OTEZLA\u00ae Apremilast Tablets","year":"2020"},{"key":"10.1016\/j.jaut.2026.103538_bib4","series-title":"PRODUCT MONOGRAPH XELJANZ\u00ae Tofacitinib Tablets","year":"2014"},{"key":"10.1016\/j.jaut.2026.103538_bib5","series-title":"PRODUCT MONOGRAPH OLUMIANT\u00ae Baricitinib Tablets","year":"2018"},{"key":"10.1016\/j.jaut.2026.103538_bib6","series-title":"PRODUCT MONOGRAPH RINVOQ\u00ae Upadacitinib extended-release Tablets","author":"Corporation","year":"2019"},{"key":"10.1016\/j.jaut.2026.103538_bib7","series-title":"Filgotinib for Treating Moderate to Severe Rheumatoid Arthritis Published","year":"2021"},{"issue":"17","key":"10.1016\/j.jaut.2026.103538_bib8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"Supp1","key":"10.1016\/j.jaut.2026.103538_bib9","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1186\/1472-6874-4-S1-S18","article-title":"The impact of arthritis on Canadian women","volume":"4","author":"Badley","year":"2004","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.jaut.2026.103538_bib10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.21663","article-title":"Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"Chakravarty","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.jaut.2026.103538_bib11","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/rheumatology\/kez565","article-title":"Rheumatoid arthritis and risk of spontaneous abortion: a Danish nationwide cohort study","volume":"59","author":"Nathan","year":"2020","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.jaut.2026.103538_bib12","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"de Man","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jaut.2026.103538_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/acr.23434","article-title":"Patterns of biologics utilization and discontinuation before and during pregnancy in women with autoimmune diseases: a population-based cohort study","volume":"70","author":"Tsao","year":"2018","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.jaut.2026.103538_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2018-213023","article-title":"Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study","volume":"77","author":"Tsao","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103538_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003739","article-title":"Medication utilisation trends during pregnancy and factors influencing adverse pregnancy outcomes in patients with rheumatoid arthritis","volume":"10","author":"Song","year":"2024","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.jaut.2026.103538_bib16","first-page":"1080","article-title":"Perinatal exposure to conventional synthetic disease-modifying anti-rheumatic drugs in women with rheumatic disease and neonatal outcomes: a population-based study","volume":"38","author":"Howren","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103538_bib17","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/acr.25502","article-title":"Pregnancy Outcomes of Targeted Synthetic Disease-Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review","volume":"77","author":"Cheng","year":"2025","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaut.2026.103538_bib18","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2026.103538_bib19","doi-asserted-by":"crossref","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res. 2020;72(4):461-488.","DOI":"10.1002\/acr.24130"},{"issue":"4","key":"10.1016\/j.jaut.2026.103538_bib20","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2026.103538_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19899296","article-title":"Baricitinib exposure during pregnancy in rheumatoid arthritis","volume":"12","author":"Costanzo","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2026.103538_bib22","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"issue":"17","key":"10.1016\/j.jaut.2026.103538_bib23","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/bdr2.1942","article-title":"Fetal exposure to tofacitinib during the first trimester: a healthy newborn case report","volume":"113","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2021","journal-title":"Birth Defects Res."},{"issue":"2","key":"10.1016\/j.jaut.2026.103538_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1753495X20948984","article-title":"Perinatal epidemiology: issues, challenges, and potential solutions","volume":"14","author":"Giannakou","year":"2021","journal-title":"Obstet. Med."},{"key":"10.1016\/j.jaut.2026.103538_bib25","series-title":"British Columbia. Perinatal Data Registry","year":"2023"},{"key":"10.1016\/j.jaut.2026.103538_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12884-015-0563-7","article-title":"Validating the British Columbia perinatal data registry: a chart re- abstraction study","volume":"15","author":"Frosst","year":"2015","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"10.1016\/j.jaut.2026.103538_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-024-03466-8","article-title":"Do individuals with inflammatory arthritis receive minimally adequate treatment for incident depression and anxiety: a population-based study","volume":"27","author":"Howren","year":"2025","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.jaut.2026.103538_bib28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2016-209562","article-title":"Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap","volume":"76","author":"Lacaille","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2026.103538_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/acr.24147","article-title":"Adherence to antimalarial therapy and risk of type 2 diabetes mellitus among patients with systemic lupus erythematosus: a population-based study","volume":"73","author":"Salmasi","year":"2021","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.jaut.2026.103538_bib30","volume":"7","author":"McCormick","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jaut.2026.103538_bib31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2018-214388","article-title":"Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study","volume":"78","author":"Avi\u00f1a-Zubieta","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jaut.2026.103538_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1155\/2012\/278495","article-title":"Development and validation of an administrative case definition for inflammatory bowel diseases","volume":"26","author":"Rezaie","year":"2012","journal-title":"Can. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103538_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-230X-14-140","article-title":"Decreasing incidence of inflammatory bowel disease in Eastern Canada: a population database study","volume":"14","author":"Leddin","year":"2014","journal-title":"BMC Gastroenterol."},{"issue":"10","key":"10.1016\/j.jaut.2026.103538_bib34","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1097\/MIB.0000000000000162","article-title":"Epidemiology of inflammatory bowel disease in Qu\u00e9bec: recent trends","volume":"20","author":"Bitton","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.jaut.2026.103538_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.24095\/hpcdp.31.3.04","article-title":"Estimating gestational age at birth: a population-based derivation- validation study","volume":"31","author":"Urquia","year":"2011","journal-title":"Chronic Dis. Inj. Can."},{"issue":"3","key":"10.1016\/j.jaut.2026.103538_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ero.2025.06.011","article-title":"Pregnancy outcomes of non-tumour necrosis factor inhibitor biologic disease-modifying antirheumatic drugs among individuals with autoimmune diseases: a scoping review and proposed framework for reporting outcomes","volume":"1","author":"Cheng","year":"2025","journal-title":"EULAR Rheumatol. Open"},{"issue":"10","key":"10.1016\/j.jaut.2026.103538_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00296-025-05968-3","article-title":"Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework","volume":"45","author":"Cheng","year":"2025","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.jaut.2026.103538_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/epirev\/mxab003","article-title":"Matching methods for confounder adjustment: an addition to the epidemiologist's toolbox","volume":"43","author":"Greifer","year":"2022","journal-title":"Epidemiol. Rev."},{"issue":"4","key":"10.1016\/j.jaut.2026.103538_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis","volume":"6","author":"Reed","year":"2019","journal-title":"Rheumatol. Ther."},{"issue":"4","key":"10.1016\/j.jaut.2026.103538_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jaut.2026.103538_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103538_bib42","article-title":"Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations","author":"Mitrova","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103538_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0035-1556745","article-title":"Identifying human teratogens: an update","volume":"4","author":"Alwan","year":"2015","journal-title":"J. Pediatr. Genet."},{"issue":"2","key":"10.1016\/j.jaut.2026.103538_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/03009748309102886","article-title":"Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis","volume":"12","author":"Ostensen","year":"1983","journal-title":"Scand. J. Rheumatol."},{"issue":"4","key":"10.1016\/j.jaut.2026.103538_bib45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/14767058.2018.1498835","article-title":"Pregnancy outcomes in women with rheumatoid arthritis: a retrospective population-based cohort study","volume":"33","author":"Aljary","year":"2020","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"1","key":"10.1016\/j.jaut.2026.103538_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12884-022-04552-y","article-title":"The role of maternal age on the risk of preterm birth among singletons and multiples: a retrospective cohort study in Lombardy, Northern Italy","volume":"22","author":"Esposito","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"10.1016\/j.jaut.2026.103538_bib47","article-title":"Low birth weight and its associated risk factors: health facility-based case-control study","volume":"15","author":"K","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jaut.2026.103538_bib48","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/art.1780400527","article-title":"Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother","volume":"40","author":"Buckley","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.jaut.2026.103538_bib49","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women who have taken leflunomide during pregnancy","volume":"62","author":"Chambers","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2026.103538_bib50","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1186\/s12884-023-06033-2","article-title":"Association between disease activity of rheumatoid arthritis and maternal and fetal outcomes in pregnant women: a systematic review and meta-analysis","volume":"23","author":"Lv","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"10.1016\/j.jaut.2026.103538_bib51","first-page":"976","article-title":"Risk of congenital anomalies in infants born to women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study","volume":"37","author":"Tsao","year":"2019","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:17:26Z","timestamp":1774041446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"alternative-id":["S0896841126000168"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103538","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perinatal use of targeted synthetic DMARDs and maternal-neonatal outcomes in autoimmune disease: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103538"}}